Olomorasib: Primary completion of P3 SUNRAY01 trial (NCT06119581) for NSCLC in Oct 2026 (Eli Lilly) - Feb 7, 2025 - Q4 2024 Results: Completion of P3 SUNRAY01 trial for NSCLC in Oct 2029; Primary completion and completion of P1/2 trial (NCT04956640) for NSCLC in Jun 2026
Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology
|